Drug Trial Radar · NCT02042196
Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
Last checked: Nov 20, 2026Latest source record: Jul 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 2013
Primary completion
May 2, 2016
Study completion May 2, 2016
Sponsor
- Lead sponsor
- University of Colorado, DenverAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Jan 22, 2014
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
As women get older and go through menopause, levels of the female reproductive hormone estradiol decrease to low levels. Also with aging, the functioning of the arteries declines. Over time this vascular dysfunction can lead to health problems such as high blood pressure and heart disease. This study is being done to help determine what causes arteries to become unhealthy in postmenopausal women, who have low levels of the female reproductive hormone estradiol. In this study we will test whether low levels of tetrahydrobiopterin (BH4), a natural substance in the body that can cause the arteries to expand, explains why arteries become unhealthy in women with low levels of estradiol. To answer this question, we will study how vascular function changes with a medication that causes a short-term increase in BH4 levels when estradiol is lowered with a medication, compared to when estradiol is normal. We will also determine whether the administration of the antioxidant vitamin C, along with the medication to increase BH4 levels, will normalize vascular health in perimenopausal and postmenopausal women, and in women who have their estradiol levels lowered.
Conditions
- Menopause
- Aging
Interventions
KUVANDrug
KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
PlaceboDrug
Placebo pills designed to match the dissolvable KUVAN pills
CetrotideDrug
Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
ClimaraDrug
0.075mg/d transdermal patch will be placed on skin.
Placebo transdermal patchDrug
Inactive transdermal patch
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in brachial artery flow-mediated dilationTime frame: 4-5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Colorado Denver
Aurora, Colorado
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.